Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...
FiercePharma2d
Verona touts 'exceptionally strong' launch of blockbuster hopeful COPD treatment Ohtuvayre
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Verona Pharma Expects Preliminary Q4 Sales Of About $36 Mln From Ohtuvayre
Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...
Verona Pharma sees Q4 net product sales revenue $36M vs. $0M a year ago
Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...
Verona posts early sales figures for Q4 and 2024
Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...
pharmaphorum2d
Verona says COPD drug is off to a flying start
Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...
Pharmaceutical Technology10d
Ensifentrine by Verona Pharma for Bronchiectasis: Likelihood of Approval
Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...